Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 8/20 | 0.47 |
| ▸ | AURKA | O14965 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.42 |
| ▸ | PLK1 | P53350 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 2/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6515113 | 0.90 | AURKA (0.48) | TRPV1AURKAKDRAURKBHDAC3 | |
| SCHEMBL6517752 | 0.88 | AURKA (0.50) | AURKAKDRAURKBHDAC1CHEK1 | |
| SCHEMBL6513140 | 0.87 | AURKA (0.49) | AURKAKDRAURKBHDAC3HDAC1 | |
| SCHEMBL6523103 | 0.86 | CHEK1 (0.55) | AURKAKDRAURKBCHEK1MAPT | |
| SCHEMBL6521705 | 0.85 | AURKA (0.51) | AURKAKDRAURKBCHEK1PLK1 | |
| SCHEMBL6513075 | 0.84 | AURKA (0.48) | AURKAKDRAURKBHDAC3HDAC1 | |
| SCHEMBL6514156 | 0.84 | AURKA (0.50) | AURKAKDRAURKBHDAC1CHEK1 | |
| SCHEMBL6514908 | 0.84 | AURKA (0.47) | AURKAKDRAURKBHDAC3HDAC1 | |
| SCHEMBL6515420 | 0.83 | AURKA (0.47) | AURKAKDRAURKBHDAC3HDAC1 | |
| SCHEMBL6519817 | 0.82 | CHEK1 (0.50) | AURKAKDRAURKBHDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050245563-A1 | Chk-1 inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-11-03 | — | — | US | disclosed |
| WO-2005028474-A2 | PYRAZOLOQUINOLINE DERIVATIVES AS CHK-1 INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245563-A1 | Chk-1 inhibitors | CHKA, CHKB, CHEK1 | TRPV1 4789/4885AURKA 78/4885KDR 1094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.